Since its creation, Yomi Pharma has established itself as a pioneering figure in research against lung cancer, particularly in the treatment of the most resistant forms of the disease. Based in Limoges, this dynamic start-up led by Camille Granet, a name increasingly cited in scientific circles, could well be a game-changer for thousands of patients around the world.
Read also:
Yomi Pharma: Innovative treatments for resistant patients
Lung cancers resistant to conventional treatments represent a major challenge for contemporary medicine. Yomi Pharma is focusing on this issue, offering new perspectives thanks to a drug in development that promises to be effective even after several cancer genetic mutations. This treatment could not only improve the quality of life of patients but also significantly increase their life expectancy, a revolution in itself.
How many people suffer from lung cancer in France and around the world?
Worldwide, in 2022 there will be more than 2.4 million new cases of lung cancer per year, or around 13% of all cancers. In France, estimates for 2023 show 52,777 new cases of lung cancer (33,438 men and 19,339 women). Lung cancer is the 3rd most common cancer in France, all sexes combined. It represents the leading cause of death from cancer in France, with 33,117 deaths estimated in 2018. The incidence of this cancer is decreasing slightly in men (-0.5% per year between 2010 and 2023) but is sharply decreasing. progression in women (+4.3% per year over the same period).
Sortilin: Key to the new therapy
During her thesis, Camille Granet discovered that the Sortilin protein, often less expressed in patients with aggressive forms of lung cancer, played a crucial role in the development of the disease. By isolating and synthesizing a specific fragment of this protein, she highlighted its anti-tumor potential. This discovery is at the origin of the drug that Yomi Pharma is developing today.
An innovative company born from academic research
The transition from academic research to entrepreneurship is not a path frequently taken in France, especially outside large centers like Paris. Yomi Pharma, however, embodies this movement, having been founded following a university thesis and thanks to the support of a local incubator which was able to recognize and promote the commercial and therapeutic potential of this research.
Local strategy, global vision
Choosing Limoges rather than Paris is a decision that reflects the philosophy of Yomi Pharma: promoting local potential while aiming for an international reach. The start-up plans to carry out its first clinical trials in Bordeaux, a choice which underlines its commitment to the Nouvelle-Aquitaine region while being part of a global development strategy.
Funding and the future of research
To move on to clinical trials, Yomi Pharma needs to raise significant funds. Already supported by the Nouvelle-Aquitaine region, the start-up is seeking to secure more funding to carry out its ambitious projects. Future successes could attract the interest of large pharmaceutical groups, essential for the large-scale production and marketing of the drug.
Recruitments and team building
With clinical trials in sight and continued development, Yomi Pharma is in the process of strengthening its team. Recruitments are planned, particularly researchers and technicians, to support the next phases of research and development.
This article explores the rise of Yomi Pharma, a biotechnology company based in Limoges, which is innovating in the treatment of lung cancer with a targeted approach to resistant forms of the disease. Led by Camille Granet, the start-up uses recent discoveries on the cortisol protein to develop a drug that could revolutionize patients’ survival and quality of life. Between financing, recruitment and clinical trials, Yomi Pharma is at the forefront of pharmaceutical research and development.
Sources :
- https://entreprises.nouvelle-aquitaine.fr/actualites/cancer-du-poumon-la-start-yomi-pharma-innove
- https://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers/Les-cancers-les-plus-frequents/Cancer-du-poumon
